Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Other Non-Current Assets: 2012-2025

Historic Other Non-Current Assets for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Sep 2025 value amounting to $3.4 million.

  • Enanta Pharmaceuticals' Other Non-Current Assets changed negligibly% to $3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.4 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $3.4 million for FY2025, which is negligibly% changed negligibly from last year.
  • According to the latest figures from FY2025, Enanta Pharmaceuticals' Other Non-Current Assets is $3.4 million, which was down 0.00% from $3.4 million recorded in FY2024.
  • Enanta Pharmaceuticals' Other Non-Current Assets' 5-year high stood at $4.0 million during FY2022, with a 5-year trough of $608,000 in FY2021.
  • In the last 3 years, Enanta Pharmaceuticals' Other Non-Current Assets had a median value of $3.4 million in 2025 and averaged $3.6 million.
  • As far as peak fluctuations go, Enanta Pharmaceuticals' Other Non-Current Assets surged by 552.63% in 2022, and later dropped by 15.32% in 2024.
  • Enanta Pharmaceuticals' Other Non-Current Assets (Yearly) stood at $608,000 in 2021, then spiked by 552.63% to $4.0 million in 2022, then remained steady at $4.0 million in 2023, then declined by 15.32% to $3.4 million in 2024, then remained steady at $3.4 million in 2025.